06. October 2025 | Adhoc News

Ad-hoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform

Korneuburg, October 6, 2025 - Ad hoc announcement

Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.

+++ End of ad-hoc announcement +++

Ad-hoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
(54 KB)